173 related articles for article (PubMed ID: 29978573)
1. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
[TBL] [Abstract][Full Text] [Related]
3. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.
Li X; Li Z; Li L; Liu T; Qian C; Ren Y; Li Z; Chen K; Ji D; Zhang M; Wang J
Cancer Res Treat; 2024 Jan; 56(1):134-142. PubMed ID: 37591782
[TBL] [Abstract][Full Text] [Related]
4. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.
Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
[TBL] [Abstract][Full Text] [Related]
6. Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.
Wang H; Ma X; Zhang B; Zhang Y; Han N; Wei L; Sun C; Sun S; Zeng X; Guo H; Li Y; Zhang Y; Zhao J; Qin Z; Liu Z; Zhang N
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e148-e153. PubMed ID: 34196110
[TBL] [Abstract][Full Text] [Related]
7. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
Pyrhönen S; Valavaara R; Modig H; Pawlicki M; Pienkowski T; Gundersen S; Bauer J; Westman G; Lundgren S; Blanco G; Mella O; Nilsson I; Hietanen T; Hindy I; Vuorinen J; Hajba A
Br J Cancer; 1997; 76(2):270-7. PubMed ID: 9231932
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
[TBL] [Abstract][Full Text] [Related]
9. Toremifene versus tamoxifen for advanced breast cancer.
Mao C; Yang ZY; He BF; Liu S; Zhou JH; Luo RC; Chen Q; Tang JL
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD008926. PubMed ID: 22786516
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population.
Yenny ; Panigoro SS; Purwanto DJ; Hidayat A; Louisa M; Andalusia R; Setiabudy R
Endocr Metab Immune Disord Drug Targets; 2019; 19(8):1198-1206. PubMed ID: 30843495
[TBL] [Abstract][Full Text] [Related]
11. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Xu Y; Sun Y; Yao L; Shi L; Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; He L; Li P; Xie Y
Ann Oncol; 2008 Aug; 19(8):1423-1429. PubMed ID: 18407954
[TBL] [Abstract][Full Text] [Related]
12. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
13. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
14. The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer.
Zeng Y; Huang K; Huang W
Pak J Pharm Sci; 2017 May; 30(3(Special)):1095-1098. PubMed ID: 28671087
[TBL] [Abstract][Full Text] [Related]
15. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
Park GC; Jung JA; Bae KS; Lim HS
J Clin Pharmacol; 2017 Sep; 57(9):1088-1096. PubMed ID: 28369967
[TBL] [Abstract][Full Text] [Related]
16. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.
Kim J; Coss CC; Barrett CM; Mohler ML; Bohl CE; Li CM; He Y; Veverka KA; Dalton JT
Int J Cancer; 2013 Mar; 132(6):1475-85. PubMed ID: 22915089
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China.
Lan B; Ma F; Han M; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Clin Breast Cancer; 2019 Apr; 19(2):e370-e375. PubMed ID: 30630678
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
19. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
20. Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.
Song D; Hu Y; Diao B; Miao R; Zhang B; Cai Y; Zeng H; Zhang Y; Hu X
BMC Cancer; 2021 Jul; 21(1):798. PubMed ID: 34246237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
